Ser1049

Site Information
AMBIGUOUS SITES: acinus (human): , ARL6IP4 iso1 (human): , ARL6IP4 iso1 (human): , ataxin‑7 (human): , ataxin‑7L1 (human): , BCL6B (human): , BHLHB5 (human): , BRD2 (human): , BRDT (human): , CAMTA2 (human): , CHD‑8 (human): , CHD‑9 (human): , CHD‑9 (human): , CIR (human): , CUL4B iso1 (human): , DACH1 (human): , DACH1 (human): , DRPLA (human): , E2F4 (human): , EDC4 (human): , EphB6 (human): , ERF (human): , FAM193B (human): , GLCCI1 (human): , GTF2IRD1 (human): , HDGF2 (human): , HEG1 (human): , HOXD4 (human): , HSPB7 (human): , ING3 (human): , JCAD (human): , JMJD6 (human): , KCNMA1 (human): , KCNMA1 (human): , KLHL1 (human): , LZTS2 (human): , MAGE‑A10 (human): , MBTPS2 (human): , MBTPS2 (human): , MLL (human): , MLLT3 (human): , MLLT3 (human): , MLLT3 (human): , MLLT3 (human): , MLLT3 (human): , MLLT6 (human): , MPRIP (human): , NAF1 (human): , NAF1 (human): , NDUFV3 iso2 (human): , neurobeachin (human): , NFE2L1 (human): , NKX6‑1 (human): , NOLC1 (human): , NPAS1 (human): , NR1D1 (human): , NRG2 (human): , NRG3 (human): , PHLPP2 (human): , PNN (human): , POU6F2 (human): , PPIG (human): , PPRC1 (human): , PPRC1 (human): , PPRC1 (human): , PRDM2 (human): , PRG4 (human): , PRR13 (human): , RANBP10 (human): , REXO1 (human): , RKHD3 (human): , RNF12 (human): , RNF12 (human): , RNF126 (human): , SALL1 (human): , SALL2 (human): , SERTAD4 (human): , SETD1A (human): , SETD1A (human): , SFRS16 (human): , SHE (human): , SNAP190 (human): , SP4 (human): , SRm300 (human): , SRm300 (human): , SRm300 (human): , SRm300 (human): , SRm300 (human): , SRm300 (human): , SYN2 (human): , Tks5 (human): , TMEM40 (human): , TMEM40 (human): , TNRC18 (human): , TNRC18 (human): , TNRC18 (human): , TNRC18 (human): , TNRC18 (human): , TNRC18 (human): , TNRC18 (human): , TSHZ3 (human): , TTC14 (human): , WDR22 (human): , ZBTB4 (human): , ZBTB4 (human): , ZC3H3 (human): , ZNF865 (human): , ZNF865 (human):
SSSSssssSSSSSSS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23143237

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 )
Relevant cell line - cell type - tissue:	BEAS-2B (epithelial) [LKB1 (human), no information] ( 1 )

References
1	Rikova K (2009) CST Curation Set: 6682; Year: 2009; Biosample/Treatment: cell line, Dana Farber BEAS LKB/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info

References

Rikova K (2009) CST Curation Set: 6682; Year: 2009; Biosample/Treatment: cell line, Dana Farber BEAS LKB/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info